Okyanos Heart Institute Announces July Seminar To Discuss Coronary Artery Disease

Top Quote Free Educational Seminar Will Provide Information About New Treatment Option Through Cardiac Cell Therapy To Patient's Suffering From Chronic Coronary Artery Disease. End Quote
  • (1888PressRelease) July 11, 2012 - FREEPORT, Bahamas - Okyanos Heart Institute (http://www.okyanos.com/), which brings a new standard of care and a better quality of life to patients with coronary artery disease (CAD) using cardiac cell therapy, has announced that it will host a free educational seminar led by Chief Medical Officer Howard Walpole, Jr., M.D., MBA, FACC, FACAI, FSCAI. In the seminar, Dr. Walpole will discuss cardiac cell therapy and the potential benefits for individuals facing coronary artery disease. The seminar will take place on Wednesday, July 18 from 2 p.m. to 4 p.m. and on Thursday, July 19 from 4 p.m. to 6 p.m. at the Intercontinental Hotel Tampa located at 4861 W. Kennedy Blvd. in Tampa, Fla. Prior to and at the conclusion of each presentation, seminar attendees will be able to speak individually with Dr. Walpole for a brief review of their own echocardiogram, EKG and nuclear scan report to determine initial eligibility for cardiac cell therapy treatment. Those who wish to learn about a new treatment option for patients who have previously had bypass surgery or stents, and who still experience symptoms associated with heart failure, such as shortness of breath and fatigue, are invited to attend. Complimentary hors d'oeuvres and beverages will be served.

    Individuals interested in attending can RSVP toll-free by phone at 1-855-659-6790 or online at http://okyanos.com/seminars. Seats are limited.

    QUOTES:
    "Okyanos Heart Institute is excited to offer a free seminar that will provide valuable information in regard to the benefits of cardiac cell therapy treatment and how this treatment can improve the lives of individuals suffering from CAD," said Matthew Feshbach, co-founder and CEO of Okyanos Heart Institute. "Dr. Walpole, a leading expert cardiologist, will discuss how Okyanos Heart Institute assists CAD patients in finding the treatment they need, and will be readily available to meet with all participants one-on-one to discuss specific situations and how cardiac stem cell therapy can help."

    "I am very eager to provide insight into cardiac cell therapy treatment for individuals suffering from CAD and to share more information about the science behind this treatment," said Walpole. "Countless individuals are suffering from the repercussions of CAD each day and are unaware of the medical options that are available. Okyanos Heart Institute offers a new standard of care and the option of a better quality of life for these individuals, and I look forward to discussing the benefits that cardiac cell therapy may provide for CAD patients."

    NEW MEDIA CONTENT:
    Okyanos LinkedIn page:
    http://www.linkedin.com/company/okyanos-heart-institute

    Okyanos Facebook page:
    https://www.facebook.com/OKYANOS

    Okyanos Twitter page:
    https://twitter.com/#!/OkyanosHeart

    ABOUT OKYANOS HEART INSTITUTE:
    Based in Freeport, The Bahamas, the Okyanos Heart Institute is a Center of Excellence (CoE) adhering to U.S. surgical center standards and led by Chief Medical Officer Howard Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI, a leader of the American College of Cardiology for many years. The mission of Okyanos Heart Institute is to bring a new standard of care and a better quality of life to patients with chronic coronary artery disease using cardiac cell therapy. The Greek god of rivers, "Okyanos" symbolizes the primary mechanism of action that these adult stem cells have on ischemic (lack of blood flow) heart tissue, the result of the plaque deposits in the coronary arteries. The stem cells, derived from a person's adipose (fat) tissue, create new blood vessels, a process known as angiogenesis. These cells facilitate blood flow in the heart and intake and use of oxygen, as measured by a rigorous clinical trial known as the PRECISE trial, as well as cardiac cell therapy trials at leading research institutions. For more information, visit http://www.okyanos.com/.

    Anjelica Cummings
    MMI Public Relations
    (919) 233-6600
    anjelica ( @ ) mmipublicrelations dot com
    http://twitter.com/MMIPR
    http://www.mmipublicrelations.com

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information